Major Research Findings

Epsilon-aminocaproic acid (EACA) is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage. 3 found that long-term antifibrinolytic therapy may lead to an increase in ischemic deficits. More recent studies indicated that early, short-term therapy may be beneficial.

Reasons for Side Effects

EACA works by inhibiting the body's fibrinolytic system, which prevents the breakdown of blood clots and helps prevent rebleeding. However, this effect can be excessive, leading to the formation of blood clots that can block blood vessels, causing side effects.

Common Side Effects

Thrombosis

EACA can increase the risk of thrombosis, as it inhibits fibrinolysis and makes it harder for clots to dissolve. 3 found that a decrease in rebleeding with long-term antifibrinolytic therapy is offset by an increase in ischemic deficits.

Gastrointestinal Disturbances

EACA may cause gastrointestinal disturbances, as it can irritate the stomach lining. 1 found that aspirin, a known side effect of tinnitus, deafness, and gastrointestinal disturbance, was more efficiently shown when a checklist was not used.

Allergic Reactions

EACA can cause allergic reactions, as it can trigger an immune response in some people.

Other Side Effects

EACA may cause other side effects, such as dizziness, headache, nausea, vomiting, rash, and itching.

Side Effect Management

Thrombosis Management

To reduce the risk of thrombosis, regular blood tests are needed to monitor for the development of blood clots while using EACA.

Gastrointestinal Disturbances Management

To reduce the risk of gastrointestinal disturbances, EACA should be taken with meals. If gastrointestinal problems arise, appropriate medications should be administered.

Allergic Reaction Management

To reduce the risk of allergic reactions, an allergy test should be conducted before using EACA. During treatment, be vigilant for signs of allergic reactions.

Other Side Effects Management

To reduce the risk of other side effects, it is crucial to follow the doctor's instructions regarding the usage of EACA. If any side effects are concerning, consult a physician.

Comparison Between Studies

Similarities

Multiple studies have shown that EACA can increase the risk of thrombosis. 3 found that long-term antifibrinolytic therapy may lead to an increase in ischemic deficits. 4 also found that EACA tended to increase the incidence of disseminated intravascular coagulation (DIC) in pregnant rats.

Differences

EACA is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage. 3 found that early, short-term therapy may be beneficial. 4 focused on preventing DIC in pregnant rats using estrogens.

Considerations for Real-Life Applications

EACA is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage. 3 found that early, short-term therapy may be beneficial. EACA should be used only as directed by a healthcare professional, and any concerns about side effects should be addressed immediately with a physician.

Limitations of Current Research

Research on EACA is still limited, particularly regarding the long-term effects of its use. Further research is needed to fully understand the long-term side effects.

Future Research Directions

Further research is needed to assess the long-term safety and effectiveness of EACA. Additionally, research is needed to optimize the dosage and duration of EACA treatment.

Conclusion

EACA is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage. 3 found that early, short-term therapy may be beneficial. However, it's essential to be aware of the potential side effects, including thrombosis, and to use EACA only under the guidance of a healthcare professional.